7-(morpholinyl)-2-(n-piperazinyl) methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs

The present invention relates to novel series of substituted 7-(morpholinyl)-2-(N-piperazinyl)-methyl thieno [2, 3-c] pyridines of the following structure of formula I, wherein R1 is H, C1-C6 alkyl, C3-C6 cycloalkyl, -C(O)R5, -S(O)2R5, -C(O)2R5, C1-C6 alkyl substituted with R6, C3-C6 cycloalkyl substituted with R6, aryl, aryl substituted with R6 or heteroaryl substituted with R6; R2, R3 and R4 are each independently H, -OH, -SH, halo, amino, cyano, -nitro, C1-C6 alkyl, C3-C6 cycloalkyl, aryl, -C(O)R5, -S(O)2R5, -C(O)2R5, -C=C(H)-R6, aminocarbonyl substituted with R6, alkylamino group substituted with R6 and optionally containing C3-C6 cycloalkyl, -alkylaminocarbonyl, arylaminocarbonyl, heteroaryl, heteroaryl substituted with H, amino, aminoalkyl or aminocycloalkyl containing C3-C6 carbon atoms, fused bicyclic or tricyclic heteroaryl containing 1, 2 or 3 heteroatoms such as N, O or S, or aryl optionally substituted with hydroxyl, hydroxylalkyl, amino, aminoalkyl, aminocarbonyl, alkynyl, cyano, halogen, aryloxy or R6; R5 is H, alkyl, amino, aminoalkyl, -N(alk)2, aryl substituted with R6, heteroaryl substituted with R6, fused heteroaryl substituted with R6 or -trifluoromethyl; R6 is H, hydroxy, halogen, cyano, nitro, amino, C1-C6 alkyl, -N(alk)2, aryl(hydroxyl)alkyl, aromatic acylamino, arylsulfonylamino, heteroarylalkenyl, heteroarylalkynyl, aromatic acyl alkynyl, arylamino or arylalkylamino.